479064-92-1 Usage
Uses
Used in Pharmaceutical Industry:
Fmoc-(R)-3-Amino-3-(4-chlorophenyl)propionic acid is used as a key building block for the synthesis of peptide-based drugs. Its unique structure and (R) configuration contribute to the development of therapeutic agents with specific biological activities and functions.
Used in Research and Development:
In the realm of scientific research, Fmoc-(R)-3-Amino-3-(4-chlorophenyl)propionic acid serves as an essential research reagent. It aids in the exploration of peptide and protein structures, functions, and interactions, furthering our understanding of biological systems and potential therapeutic targets.
Used in Biochemical Studies:
Fmoc-(R)-3-Amino-3-(4-chlorophenyl)propionic acid is utilized in biochemical studies to investigate the properties and mechanisms of peptides and proteins. Its incorporation into peptide sequences allows for the examination of structure-function relationships and the elucidation of biological pathways.
Used in Peptide Synthesis:
Fmoc-(R)-3-Amino-3-(4-chlorophenyl)propionic acid is employed as a crucial component in peptide synthesis, particularly in solid-phase synthesis techniques. Its Fmoc protecting group ensures efficient and selective coupling of amino acids, facilitating the production of peptides with desired sequences and properties.
Overall, Fmoc-(R)-3-Amino-3-(4-chlorophenyl)propionic acid is a valuable compound in the fields of pharmaceuticals, research, and biochemical studies, playing a pivotal role in the synthesis and understanding of peptides and proteins.
Check Digit Verification of cas no
The CAS Registry Mumber 479064-92-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,9,0,6 and 4 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 479064-92:
(8*4)+(7*7)+(6*9)+(5*0)+(4*6)+(3*4)+(2*9)+(1*2)=191
191 % 10 = 1
So 479064-92-1 is a valid CAS Registry Number.
InChI:InChI=1/C24H20ClNO4/c25-16-11-9-15(10-12-16)22(13-23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)/t22-/m1/s1
479064-92-1Relevant academic research and scientific papers
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
